Bulk Pharmaceutical API Sources for VORINOSTAT

Bulk Pharmaceutical API Sources for VORINOSTAT

Vendor	Vendor Homepage	Vendor Sku	API Url
Exclusive Chemistry Ltd		EC-000.2057
NovoSeek		5311
MolPort		MolPort-003-850-293
Hangzhou APIChem Technology		AC-1923
ABI Chem		AC1L1K2K

Vorinostat Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current global supply chain for bulk vorinostat Active Pharmaceutical Ingredient (API), identifying key manufacturers, their production capacities, regulatory compliance, and potential supply chain risks. Understanding these elements is critical for pharmaceutical companies engaged in the development, manufacturing, and commercialization of vorinostat-based therapies.

What is Vorinostat?

Vorinostat, also known by its developmental name SAHA, is a histone deacetylase (HDAC) inhibitor. It is approved for the treatment of symptomatic cutaneous T-cell lymphoma (CTCL) in patients with Stage IIB or III disease. Vorinostat functions by inhibiting HDAC enzymes, leading to hyperacetylation of histones, which can alter gene expression and induce cell differentiation, cell cycle arrest, or apoptosis in cancer cells.

Global Vorinostat API Manufacturing Footprint

The production of vorinostat API is concentrated in a limited number of specialized chemical manufacturers, primarily located in China and India. These regions offer cost advantages and established expertise in complex organic synthesis.

Key API Manufacturers

Several manufacturers have demonstrated capabilities in producing vorinostat API at commercial scale. These include:

• Wuxi AppTec (China): A leading Contract Development and Manufacturing Organization (CDMO) with extensive experience in API synthesis. Wuxi AppTec offers integrated services from process development to commercial manufacturing, holding regulatory filings with major health authorities.
• Pharmatech (India): An established Indian API producer with a portfolio of oncology drugs. Pharmatech possesses Good Manufacturing Practice (GMP) compliant facilities and has supplied vorinostat API to global markets.
• Vivimed Labs (India): Another significant Indian pharmaceutical ingredient manufacturer with a presence in regulated markets. Vivimed Labs has a track record of supplying APIs for various therapeutic areas, including oncology.
• Syngene International (India): A subsidiary of Biocon, Syngene is a research and manufacturing services company capable of producing complex APIs. Their capabilities extend to process optimization and large-scale manufacturing.

Estimated Production Capacities

Precise production capacities for vorinostat API are proprietary and fluctuate based on demand and manufacturer investment. However, based on general industry estimates for similar complex small molecules, key manufacturers likely possess:

• Annual Capacity: Ranging from 100 kg to 1,000 kg per annum per facility. This capacity is scalable based on customer demand and contract manufacturing agreements.
• Lead Times: Typical lead times for commercial-scale API batches can range from 4 to 8 months, from order placement to delivery, depending on existing production schedules and raw material availability.

Regulatory Compliance and Quality Standards

The sourcing of vorinostat API necessitates adherence to stringent regulatory requirements to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP)

All commercial-grade vorinostat API intended for use in pharmaceutical products must be manufactured in GMP-certified facilities. Key regulatory bodies that inspect and certify these facilities include:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA) of Japan
• Central Drugs Standard Control Organisation (CDSCO) of India

Manufacturers commonly hold a Drug Master File (DMF) with the FDA or equivalent documentation for other regulatory agencies. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.

Quality Specifications

Typical quality specifications for vorinostat API include:

• Purity: Greater than 99.0% by High-Performance Liquid Chromatography (HPLC).
• Related Substances: Individual impurities not exceeding 0.10%. Total impurities not exceeding 0.50%.
• Residual Solvents: Compliant with ICH Q3C guidelines.
• Heavy Metals: Within acceptable limits as per pharmacopoeial standards (e.g., USP, EP).
• Particle Size Distribution: Controlled to ensure consistent dissolution profiles in the final dosage form.

Recent Regulatory Actions

Information on specific FDA warnings or recalls related to vorinostat API manufacturing is not publicly prominent. However, general FDA enforcement actions against API manufacturers in China and India for GMP violations serve as a benchmark for diligence in supplier qualification. Companies must conduct thorough audits and quality agreements.

Supply Chain Dynamics and Risk Assessment

The vorinostat API supply chain is characterized by several factors that influence availability, cost, and risk.

Key Raw Materials and Intermediates

The synthesis of vorinostat involves multiple chemical steps utilizing specialized reagents and intermediates. Common starting materials can include substituted anilines and specific acylating agents. The availability and cost of these precursors are critical to the overall API production economics. Supply chain disruptions at the level of these early-stage raw materials can impact vorinostat API availability.

Geographic Concentration Risks

The reliance on a limited number of manufacturers in specific geographic regions poses inherent risks. These include:

• Geopolitical Instability: Trade disputes, tariffs, or political unrest in manufacturing regions can disrupt supply.
• Environmental Regulations: Increasingly stringent environmental regulations in China and India can lead to temporary shutdowns of manufacturing facilities for compliance upgrades, impacting output.
• Natural Disasters: Earthquakes, floods, or other natural events can affect production capabilities.
• Pandemic Events: As demonstrated by COVID-19, global health crises can lead to widespread manufacturing shutdowns, labor shortages, and transportation disruptions.

Intellectual Property Landscape

While the core patent for vorinostat has expired, allowing for generic development, process patents for novel synthesis routes or polymorphic forms can still exist. Pharmaceutical companies seeking to source API must ensure their chosen manufacturer’s process does not infringe on any active process patents. A thorough Freedom to Operate (FTO) analysis is recommended.

Cost Drivers

The cost of vorinostat API is influenced by:

• Raw Material Costs: Fluctuations in the prices of key precursors.
• Manufacturing Complexity: The multi-step synthesis and purification processes.
• Regulatory Compliance: Costs associated with maintaining GMP standards and regulatory filings.
• Economies of Scale: Larger batch sizes generally lead to lower per-kilogram costs.
• Supply and Demand: Market demand relative to manufacturer capacity.

Strategies for Securing Vorinostat API Supply

A robust supply chain strategy for vorinostat API involves diversification and proactive risk management.

Dual Sourcing

Engaging with at least two qualified API manufacturers, preferably in different geographic locations, mitigates risks associated with single-source dependency. This provides redundancy in case of unforeseen supply disruptions.

Supplier Qualification and Auditing

A comprehensive supplier qualification program is essential. This includes:

• Technical Capability Assessment: Evaluating manufacturing processes, quality control systems, and analytical capabilities.
• Regulatory Compliance Audit: Verifying GMP certifications, inspection histories, and DMF status.
• Financial Stability Check: Assessing the long-term viability of the supplier.
• Site Audits: On-site inspections of manufacturing facilities to ensure adherence to standards.

Long-Term Supply Agreements

Establishing long-term supply agreements with preferred manufacturers can secure pricing, ensure dedicated capacity, and foster collaborative relationships for process improvement and issue resolution.

Inventory Management

Maintaining strategic safety stock levels of the API can provide a buffer against short-term supply interruptions. The optimal inventory level depends on demand variability, lead times, and the cost of holding inventory.

Key Takeaways

The global supply of vorinostat API is primarily sourced from manufacturers in China and India, with companies like Wuxi AppTec, Pharmatech, Vivimed Labs, and Syngene International being notable players. Sourcing requires strict adherence to GMP standards, validated analytical methods, and careful attention to regulatory filings (DMFs). Key risks to the supply chain include geographic concentration, geopolitical events, stringent environmental regulations, and raw material availability. Pharmaceutical companies should implement dual-sourcing strategies, conduct thorough supplier qualification and auditing, and establish long-term supply agreements to ensure a stable and compliant supply of vorinostat API.

Frequently Asked Questions

What is the typical purity requirement for vorinostat API for pharmaceutical use?

Vorinostat API for pharmaceutical use typically requires a purity of greater than 99.0% as determined by High-Performance Liquid Chromatography (HPLC).

Are there any known process patents that could impact vorinostat API sourcing?

While the primary composition of matter patent for vorinostat has expired, companies should conduct a Freedom to Operate (FTO) analysis to identify any active process patents for novel synthesis routes or polymorphic forms that could affect sourcing options.

What are the primary risks associated with sourcing vorinostat API from China and India?

Primary risks include geopolitical instability, evolving environmental regulations that can lead to production shutdowns, natural disasters, and global health crises impacting manufacturing and logistics.

How does the geographic concentration of API manufacturing affect pricing?

Geographic concentration can lead to price volatility. Limited competition and potential supply disruptions due to regional issues can increase API costs, especially during periods of high demand or supply chain stress.

What is the role of a Drug Master File (DMF) in vorinostat API sourcing?

A DMF, filed with regulatory agencies like the FDA, contains confidential manufacturing details. It allows API users to reference the manufacturer’s filing in their own drug product applications without direct access to the proprietary information, streamlining the regulatory review process.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Q3C(R6): Impurities: Guideline For Residual Solvents. [3] United States Pharmacopeia. (n.d.). General Chapter <232> Elemental Impurities—Limits. [4] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing/good-manufacturing-practice